S&P 500   4,594.11 (+0.61%)
DOW   35,861.51 (+0.34%)
QQQ   382.45 (+1.20%)
AAPL   149.62 (+0.66%)
MSFT   309.95 (+0.59%)
FB   322.74 (-1.81%)
GOOGL   2,778.25 (+1.07%)
TSLA   1,082.53 (+5.63%)
AMZN   3,410.00 (+2.70%)
NVDA   249.07 (+7.52%)
BABA   173.30 (-1.63%)
NIO   42.60 (+3.22%)
CGC   13.49 (-0.59%)
GE   108.83 (+3.35%)
AMD   126.49 (+3.38%)
MU   69.50 (+1.08%)
T   25.67 (+0.12%)
F   16.11 (+0.69%)
ACB   7.09 (-1.25%)
DIS   172.88 (+0.51%)
PFE   43.26 (+0.25%)
BA   214.16 (+0.61%)
AMC   36.51 (-0.87%)
S&P 500   4,594.11 (+0.61%)
DOW   35,861.51 (+0.34%)
QQQ   382.45 (+1.20%)
AAPL   149.62 (+0.66%)
MSFT   309.95 (+0.59%)
FB   322.74 (-1.81%)
GOOGL   2,778.25 (+1.07%)
TSLA   1,082.53 (+5.63%)
AMZN   3,410.00 (+2.70%)
NVDA   249.07 (+7.52%)
BABA   173.30 (-1.63%)
NIO   42.60 (+3.22%)
CGC   13.49 (-0.59%)
GE   108.83 (+3.35%)
AMD   126.49 (+3.38%)
MU   69.50 (+1.08%)
T   25.67 (+0.12%)
F   16.11 (+0.69%)
ACB   7.09 (-1.25%)
DIS   172.88 (+0.51%)
PFE   43.26 (+0.25%)
BA   214.16 (+0.61%)
AMC   36.51 (-0.87%)
S&P 500   4,594.11 (+0.61%)
DOW   35,861.51 (+0.34%)
QQQ   382.45 (+1.20%)
AAPL   149.62 (+0.66%)
MSFT   309.95 (+0.59%)
FB   322.74 (-1.81%)
GOOGL   2,778.25 (+1.07%)
TSLA   1,082.53 (+5.63%)
AMZN   3,410.00 (+2.70%)
NVDA   249.07 (+7.52%)
BABA   173.30 (-1.63%)
NIO   42.60 (+3.22%)
CGC   13.49 (-0.59%)
GE   108.83 (+3.35%)
AMD   126.49 (+3.38%)
MU   69.50 (+1.08%)
T   25.67 (+0.12%)
F   16.11 (+0.69%)
ACB   7.09 (-1.25%)
DIS   172.88 (+0.51%)
PFE   43.26 (+0.25%)
BA   214.16 (+0.61%)
AMC   36.51 (-0.87%)
S&P 500   4,594.11 (+0.61%)
DOW   35,861.51 (+0.34%)
QQQ   382.45 (+1.20%)
AAPL   149.62 (+0.66%)
MSFT   309.95 (+0.59%)
FB   322.74 (-1.81%)
GOOGL   2,778.25 (+1.07%)
TSLA   1,082.53 (+5.63%)
AMZN   3,410.00 (+2.70%)
NVDA   249.07 (+7.52%)
BABA   173.30 (-1.63%)
NIO   42.60 (+3.22%)
CGC   13.49 (-0.59%)
GE   108.83 (+3.35%)
AMD   126.49 (+3.38%)
MU   69.50 (+1.08%)
T   25.67 (+0.12%)
F   16.11 (+0.69%)
ACB   7.09 (-1.25%)
DIS   172.88 (+0.51%)
PFE   43.26 (+0.25%)
BA   214.16 (+0.61%)
AMC   36.51 (-0.87%)
ASX:GTG

Genetic Technologies Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive GTG News and Ratings via Email

Sign-up to receive the latest news and ratings for Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.


About Genetic Technologies

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Diagnostics & Research
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$120,554.00
Book Value
A$0.00 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Genetic Technologies (ASX:GTG) Frequently Asked Questions

What stocks does MarketBeat like better than Genetic Technologies?

Wall Street analysts have given Genetic Technologies a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Genetic Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Genetic Technologies' key executives?

Genetic Technologies' management team includes the following people:
  • Mr. Phillip Hains C.A., M.B.A., B Bus, CA, MBA, Chief Financial Officer (Age 60)
  • Mr. Stanley Sack, Chief Operating Officer (Age 57, Pay $318.28k)
  • Dr. Richard Allman, Chief Scientific Officer (Age 61, Pay $188.21k)
  • Dr. Jerzy Muchnicki MBBS, Chief Medical Officer & Exec. Director (Age 64, Pay $153.11k)
  • Mr. Simon Morriss, Chief Exec. Officer
  • Mr. Paul Keith Mathieson Viney B. Bus, FCPA, FGIA, FCI, Consultant
  • Mr. Justyn Stedwell, Company Sec. (Age 40)

What other stocks do shareholders of Genetic Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genetic Technologies investors own include Viralytics (VRACY) and Orthocell (OCC).

What is Genetic Technologies' stock symbol?

Genetic Technologies trades on the ASX under the ticker symbol "GTG."

How much money does Genetic Technologies make?

Genetic Technologies has a market capitalization of $0.00 and generates $120,554.00 in revenue each year.

What is Genetic Technologies' official website?

The official website for Genetic Technologies is www.gtglabs.com.

How can I contact Genetic Technologies?

The company can be reached via phone at 61 3 8412 7000.


This page was last updated on 10/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.